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AbstrAct
Introduction One in five men is likely to receive a 
diagnosis of prostate cancer (PCa) by the age of 85 years. 
Men diagnosed with low-risk PCa may be eligible for 
active surveillance (AS) to monitor their cancer to ensure 
that any changes are discovered and responded to in a 
timely way. Communication of risk in this context is more 
complicated than determining a numerical probability 
of risk, as patients wish to understand the implications 
of risk on their lives in concrete terms. Our study will 
examine how risk for PCa is perceived, experienced and 
communicated by patients using AS with their health 
professionals, and the implications for treatment and care.
Methods and analysis This is a proof of concept 
study, testing out a multimethod, qualitative approach 
to data collection in the context of PCa for the first time 
in Australia. It is being conducted from November 2016 
to December 2017 in an Australian university hospital 
urology clinic. Participants are 10 men with a diagnosis 
of localised PCa, who are using an AS protocol, and 5 
health professionals who work with this patient group 
(eg, urologists and Pca nurses). Data will be collected 
using observations of patient consultations with health 
professionals, patient questionnaires and interviews, and 
interviews with healthcare professionals. Analysis will be 
conducted in two stages. First, observational data from 
consultations will be analysed thematically to encapsulate 
various dimensions of risk classification and consultation 
dialogue. Second, interview data will be coded to derive 
meaning in text and analysed thematically. Overarching 
themes will represent patient and health professional 
perspectives of risk communication.
Ethics and dissemination Ethical approval for the 
study has been granted by Macquarie University Human 
Research Ethics Committee, approval 5201600638. 
Knowledge translation will be achieved through 
publications, reports and conference presentations to 
patients, families, clinicians and researchers.
IntroductIon
Prostate cancer (PCa) is the fourth leading 
cause of death among Australian men1 and 
is the most commonly diagnosed cancer for 
men in North America and Europe. Age-ad-
justed incidence rates are 85.6 per 100 000 
for North America and 59.3 per 100 000 for 
Europe,2 while in Australia, an estimated 
18 138 new cases were diagnosed in 2016.3 
Risk of developing PCa is strongly associated 
with age, with one in five men likely to receive 
a diagnosis by the age of 85 years.1 4
Some localised cancers have a very low 
risk of metastasising, especially those of low 
histological grade and of low volume, and are 
unlikely to cause death.5 The more aggressive 
form of PCa, if untreated, can metastasise to 
bone, lymph nodes and other organs, causing 
substantial morbidity and eventual death.6 
Low-risk cancers are thought to be genetically 
distinct from the more aggressive forms and, 
if diagnosed accurately, do not require treat-
ment, and these men are typically eligible 
for active surveillance  (AS).7 AS fundamen-
tally involves patients and clinicians making 
judgements about the balance of risks of 
PCa against the risks of definitive treatment, 
in addition to the disadvantages and risks 
implicated in the surveillance process, which 
can involve invasive and discomforting biop-
sies, ultrasounds and multiparametric MRI 
scans.8 9
AS is used instead of active treatments 
such as radiotherapy and prostatectomy and 
involves regular monitoring for possible 
progression.10 The purpose of AS is multifar-
ious, including to help mitigate the uncer-
tainty arising from the imaging and prostate 
tissue biopsy absolutely classifying cancer as 
low risk,8 while offering patients a choice of 
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strengths and limitations of this study
 ► As a proof of concept study, the small sample size 
and single setting limit the scope of the findings. 
Even so, this allows richer data and more detailed 
accounts than would be possible were this a larger, 
more widespread study.
 ► Information gathered from this study could closely 
inform the eventual development of patient-centric 
risk assessment procedures, for national and 
international application.
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avoiding radical treatments (and their side effects) and 
enabling timely curative treatments if cancer progression 
is indicated. Prostate biopsy is usually a random sampling 
of the gland, and high-grade cancers may be missed. 
Multiparametric MRI scans may not visualise up to 15% 
of high-grade cancers.11 This means that a proportion of 
men with apparent low-risk cancer have undetected high-
risk disease which may be identified on the AS protocol so 
that potentially curative therapy can be instigated. Cura-
tive therapy, which may include surgery, radiation therapy 
and hormonal therapy, can have serious side effects on 
patients’ bladder and bowel continence, erectile function, 
fertility and hormone balance,12 13 requiring a range of 
health services to manage these acquired complications. 
Life-saving measures present men and their families with 
the dilemma of how to manage the effects of treatment 
on their lifestyle and well-being.
Men undertaking AS generally have good quality of 
life14 and comparable or lower levels of distress than 
those who undertake treatment.15 However, many men 
decide against AS, even when medically appropriate.16 
In addition, between 13% and 50% of patients with AS go 
on to a curative treatment programme in the absence of 
an objective increased risk,17 18 as a result of raised anxiety 
about cancer.18–20
The risk assessment procedures of AS include pros-
tate-specific antigen (PSA) blood tests approximately 
every 3 months, digital rectal examinations (DREs) 
every 6 months, 12 monthly MRI scans and repeat biop-
sies every 2–3 years or earlier if indicated by an abnor-
mally elevated PSA level.21 22 There are still uncertainties 
regarding the scheduling of these tests and the extent to 
which each of the results predicts progression,21 23 24 and 
this may affect the uptake of AS.10 Research suggests that 
the probability of men on AS remaining progression-free 
at 2, 5 and 10 years is relatively high (91%, 76% and 
70% respectively).25 26 In addition, recent research indi-
cates that patients classified with an intermediate risk of 
progression have similar levels of survival and progres-
sion as men at low risk, and thus AS is increasingly being 
offered to these men as well, as an alternative option to 
other action.27 28
risk communication in As
Risk has been defined as the probability of a particular 
event happening,29 such as risk of PCa metastasising. Risk 
is typically expressed numerically,30 such as the percentage 
of patients who will get side effects from curative treat-
ments, the probability of PCa progression or death at 10 
years for those currently on AS. However, perceptions and 
understandings of certainties and uncertainties around 
such an event are highly individualised, influenced 
not only by controllability of clinical outcomes but also 
by gender issues and social factors.31 Consequently, we 
aim to identify definitions of risk, from men’s own expe-
riences of AS, rather than from a predetermined or clini-
cally driven assumption of what risk means for those being 
assessed for AS and those undertaking the treatment.
Monitoring procedures in AS, including DRE and PSA 
testing,12 are invasive and potentially embarrassing for 
patients.32 Despite this, test results that show no change 
in health status and that are given during AS consulta-
tions with healthcare professionals can be reassuring for 
men. In effect, as past research in oncology demonstrates, 
communication of risk is more complicated than just a 
numerical probability of risk, with patients wanting to 
know about what is a difficult issue to discuss: the impli-
cations of risk on their lives and mortality in concrete 
terms.33 Interview studies exploring more general issues 
in AS suggest that communication is not always effective: 
patients report uncertainty regarding the meaning of 
their diagnosis, conflicting information about treatments 
and AS, and there is difficulty in understanding informa-
tion provided by clinicians.34 35
Together these findings suggest that patients’ individual 
perceptions of risk are also shaped by the conversations 
that takes place with clinicians during consultations and 
are influenced both by what people bring to the consul-
tation and by what influences them during the consulta-
tion, which is highly dependent on the conversations that 
ensue, all of which affects psychosocial well-being and 
commitment to AS. Research is required to determine 
whether this is indeed the case. Given the intersubjective 
nature of risk communication, we need to explore both 
patients’ and clinicians’ perceptions of risk and priori-
ties about risk communication in AS, as well as the form 
discussions of risk take during consultations (eg, formal 
risk assessment and informal conversation). Further-
more, given the potentially protracted nature of both 
AS and PCa, patients’ needs for information about risks 
may change as their prioritisation of certain risks (such 
as infection through repeat biopsies and interruptions 
to everyday life) over other risks (for instance, death 
through PCa progression and side effects of other treat-
ments) changes.
study objectives
The primary objective of the study is to examine how risk 
for PCa is perceived, experienced and communicated in 
the context of AS, and what implications this has for treat-
ment and care. From this, our secondary objectives are 
as follows:
1. to clarify how patients and their healthcare 
professionals define risk, experience risk and prioritise 
the risks involved in AS for PCa;
2. to reveal the form that discussions take and the differ-
ences between patients’ and clinicians’ views;
3. to disclose the impact of discussions of risk assess-
ment results and their effect on the consultative pro-
cess;
4. to assess patients’ needs for further information, 
further discussions of risk and ongoing clinical sup-
port;
5. to identify optimal strategies for clinicians to 
communicate risk more clearly in line with patients’ 
needs and expectations.
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MEthods And AnAlysIs
study design
This is a multiperspectival, multimethod, qualitative proof 
of concept study undertaken at a single site in Australia to 
test out the use and value of mixed qualitative data collec-
tion and analysis methods in this context. Data will be 
collected using observations, patient questionnaires and 
interviews, and interviews with healthcare professionals 
will also be undertaken.36 Principles of applied thematic 
analysis37 will form the theoretical underpinnings of the 
analysis work. An applied thematic analysis of interview 
transcripts, informed and enriched by notes taken during 
observed consultations, lends itself to the proposition 
that in order to understand the world, one must answer 
research problems practically, from the ground up, and 
from a ‘real world’ perspective.37 With these principles in 
mind, data will be gathered in situ, and knowledge will be 
built over time, as textual data are thematically analysed. 
In this study, observational note taking will complement 
in-depth, semistructured interviews, with clinicians and 
patients, and both data sets will be considered corrob-
oratively so that notes from observations add detail 
and nuance to understandings of how consultations 
are conducted. This will be embellished by clinicians’ 
and patients’ interview question responses. As a clearer 
picture of the topic area is revealed, through textual 
evidence, theory development will be enabled. As in the 
Grounded Theory approach, in applied thematic analysis, 
theory is inductively derived as data are gathered, and it is 
only realised once a full data set is complete, when cate-
gories and concepts within texts can be identified and 
examined. Once complete, these can then be linked in to 
formal theoretical models.38
sample and setting
Setting
The university hospital urology clinic where this study will 
take place is one of only 26 in Australia with a dedicated 
Prostate Cancer Specialist Nurse, who is the single point 
of contact for patients and their families throughout their 
PCa management and treatment. Consultations for local-
ised PCa at the university hospital urology clinic with a 
urologist or specialist nurse involve clinician–patient 
discussions about initial tests (eg, confirmatory biop-
sies), cancer diagnosis and prognosis, test results and AS 
and other treatment options. Hence, the clinic has been 
chosen as the study setting in view of its identification 
as an important consultation environment in which risk 
and AS may be communicated with a range of healthcare 
professionals and treatments negotiated through multiple 
consultations between patients and health professionals. 
This creates a useful setting to study experiences of, and 
communications about, risk in AS for PCa.
Participants
A minimum of 10 patients, recently diagnosed with PCa 
and/or undertaking an AS protocol through a university 
hospital urology clinic, will be recruited. We anticipate 
that the sample size in this proof of concept study will 
result in saturation, based on our previous work in breast 
cancer.29 Patients will be sampled based on their meeting 
the study inclusion criteria: (a) men over the age of 18 
years, (b) diagnosed with localised PCa (c) considered 
a candidate for AS or (d) already on an AS protocol. 
Medical criteria for inclusion are based on the D’Amico 
and Smith39 classification system: Gleason sum six or less 
(Gleason 3+3=6, or Gleason 3+4 =7 if low volume on biop-
sies (one positive biopsy)); PSA 10 mg/mL or less; and 
T1c-T2a disease (T1c (impalpable) or T2a (unilateral 
palpable)). In addition, inclusion may also be defined by 
volume of cancer on biopsy.
Exclusion criteria include (a) men under the age of 18 
years, (b) men who the dedicated clinician or members 
of the clinical team deem unsuitable for participation due 
to physical, cognitive or emotional risk, or as a result of 
communication barriers, and (c) non-English speakers. 
Additionally, a sample of five healthcare professionals 
from the multidisciplinary PCa team, including urologists, 
surgeons and the Pca Specialist Nurse, will be recruited.
Recruitment procedure
The study is being conducted from November 2016 to 
December 2017. During the recruitment period, patients 
who are due to come in for a consultation at the clinic, and 
who meet the study inclusion criteria, will be contacted. 
Eligible participants will be identified by the urologists 
and the Prostate Cancer Specialist Nurse during urology 
clinic sessions. A researcher attending the clinic will then 
approach the patient to ascertain their interest in partic-
ipation. Those willing to be involved will sign a consent 
form agreeing to have their next consultation observed 
and to take part in an interview with a researcher from 
the study team. The first 10 patients who meet the study 
inclusion criteria and who consent to participate during 
the agreed time frame will form the patient cohort.
Health professional recruitment will be achieved using 
purposive sampling. Five members of the multidisci-
plinary team will be approached to take part in inter-
views, with emphasis on gathering a diverse range of 
professional opinions and a cross section of professional 
views from those most likely to work with patients with AS.
data collection
Data will be collected using four methods: observations 
of consultations for localised PCa, between male patients 
eligible for, or currently on, an AS protocol; a patient 
survey; patient interviews; and healthcare professional 
interviews (table 1).
Observations of consultations
The first stage of data collection will involve observations 
of 10 PCa consultation sessions. Observational method is 
a qualitative research technique that allows an indepen-
dent observer to document an event in its natural setting.40 
They are useful methods to employ in health services 
research because they allow in-depth examinations to 
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Table 1 Study objectives and associated data collection methods
Study objective Data collection methods
1 Clarify how patients and their multidisciplinary teams define risk, experience risk and 
prioritise the risks involved in AS for PCa
Observation of consultation
Patient questionnaire
Patient interview
Healthcare professional interview
2 Reveal the form that discussions take and differences between patients’ and 
clinicians’ views.
Observation of consultation
Patient interview
Healthcare professional interview
3 Disclose the impact of discussions of risk assessment results and their effect on the 
consultative process
Observation of consultation
Patient interview
4 Assess patients’ needs for further information, further discussions of risk and 
ongoing clinical support
Patient questionnaire
Patient interview
5 Identify optimal strategies for urologists to communicate risk more clearly in line with 
patients’ needs and expectations.
Observation of consultation
Patient interview
Healthcare professional interview
AS, active surveillance; PCa, prostate cancer.
take place of what people (eg, patients and clinicians) 
actually do, rather than just what they say they do. Obser-
vation will enable the study team to explore communi-
cation in PCa consultations in detail, as they take place, 
and in the natural practice setting. We will base our obser-
vations on the premise that one must examine both the 
depicted context and the content of an encounter at one 
and the same time—what van Manen13 describes as a 
mixture of the semantic and mantic stimuli.41 Thus, we 
will consider the setting within which the consultations 
take place (including the rooms used, how clinicians and 
patients face one another, what events unfold and how 
frequently), the spoken word (such as the emphasis given 
to certain phrases, the topics discussed and authorial 
presence) and the non-verbal cues (such as gestures and 
body language, and emotions as expressed).42
Audio recordings will provide a detailed record of the 
consultation, and field notes will be used to document 
the visual elements. Observed consultations will be 
undertaken with a named study researcher present. With 
consent, the researcher will audio-record the consulta-
tion. An observation checklist will be used to document 
discussions of treatment options, risk classification and 
assessment procedures and plans for future treatment 
and care. The timing of discussion topics, in the context 
of the patient’s journey through the system, will be 
noted, alongside the language used to convey risk (eg, 
probabilities and jargon) and who (patient or healthcare 
professional) brings up issues related to risk. Interac-
tions that reflect or contradict the notion of shared deci-
sion-making procedures and negotiated care43 will also be 
identified. Finally, the researcher will note body language 
and non-verbal exchanges between the patient and the 
healthcare professional.
Patient questionnaire
Before commencing patient interviews, patient partic-
ipants will complete a short, written questionnaire to 
provide the team with demographic details and a back-
ground of their clinical history. These details will assist 
with contextualising their interview accounts.
Patient interviews
Following observed consultations, interviews with patients 
will be conducted. Interview questions will be semistruc-
tured to provide further information on what risk means 
to patients, and perceptions of risk communication, from 
the perspectives of the study participants (table 2). Risk 
may include risk of cancer with and without active treat-
ment as well as the risk of different kinds of side effects 
(physical and emotional) from different types of treat-
ments, including AS. Moreover, there are at least two 
different components of each of these risks: likelihood 
perceptions and severity perceptions. Interview ques-
tions will allow for expansion on any themes that arise. 
To explore the topics, in-depth interviews are expected 
to take between 30 and 40 min. Interview data will help 
to contextualise the observation findings, clarify any 
inconsistencies or misunderstandings that were identi-
fied and further develop our understanding of patients’ 
and health professionals’ perceptions and experiences of 
risk in PCa.
Interviews will be conducted face-to-face or by tele-
phone at the participant’s convenience. A patient inter-
view schedule will cover perceptions of risk and risk 
status, experiences of formal and informal risk assess-
ment and patients’ priorities regarding the different risks 
involved in PCa. It will also ensure that patients’ percep-
tions and expectations of AS and other PCa treatments, 
decision making around treatment and the trajectory of 
patient experience—from diagnosis through consultation 
for PCa—are aired. Finally, patients will be asked about 
the current sources of information they access for details 
about their risk in PCa, expectations and preferences for 
information in the future and their general aspirations 
for future health and well-being in the context of PCa.
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Table 2 Patient interview schedule
Topics Exemplar questions
1 Experiences of information about risk in the oncology consultation Can you tell me a bit about your experience of 
being diagnosed with prostate cancer? How 
did you come to understand what that meant?
2 Personal definitions of risk in the context of prostate cancer and active 
surveillance
What do you consider to be a risk in prostate 
cancer? Why?
3 Priorities regarding risks in prostate cancer and active surveillance What are you most concerned about with your 
diagnosis of prostate cancer?
4 Whether priorities regarding risk in prostate cancer and active 
surveillance have changed.
Have your concerns changed since you were 
initially diagnosed?
5 The extent they consider these priorities as taken into account by health 
professionals
How have your doctor and other health 
professionals responded to your concerns?
6 Views and experiences on risk assessment and their risk classification Have you undergone a formal risk assessment 
for your prostate cancer? If so, what was that 
like? What is your risk classification?
If not, has your doctor provided you details 
regarding your risk in prostate cancer? Have 
they talked about prognosis?
Can you tell me about your experience of 
prostate cancer testings? How have you 
found receiving the results of these tests?
7 Perceptions and expectations of active surveillance What do you know about active surveillance?
8 How active surveillance has been discussed with health professionals What has your doctor told you about active 
surveillance? How useful has this information 
been?
9 Treatment decisions, how they are made and by whom, how care is 
negotiated with healthcare professionals.
What about discussing other treatments with 
your doctor?
10 Their experiences of discussing risk in clinical consultations for prostate 
cancer
Can you tell me about your experience of 
talking to your doctors about your diagnosis 
and what it means?
11 Patients’ aspirations for future health and well-being What are your hopes for your treatment?
Health professional interviews
An interview schedule for healthcare professionals 
will comprise views and expectations for risk commu-
nication and risk assessment, whether and how risk 
communication procedures change depending on the 
patient case, advice-giving style and approach to nego-
tiated care. Healthcare professionals will be asked to 
reflect on perceived patient need and their personal 
preference regarding AS and other treatments for 
PCa.
data analysis
Analysis of observational and interview data will be 
conducted in two stages. In line with applied thematic 
analysis, we intend to use a ‘bottom-up’ approach to 
both the observational and interview data, with conclu-
sions derived from these data sets, and new insights 
emerging as time progresses. Once no new insights are 
forthcoming, the applied thematic analysis framework 
is said to have reached a point of saturation, with no 
new categories emergent.44
Stage 1: observational data
Observational data analysis will commence as data are 
collected and continue as additional data come on board 
in order to build a detailed understanding of each consul-
tation. In documenting observations, the researcher will 
act as the ‘research instrument’, recording precisely 
what happens and also ‘personal reactions to events, and 
changes in his or her views over time’ (p184).40 These 
will be considered researchers’ field notes, forming the 
basis of a system for classifying clinical interactions. By 
using this staged data capture method, the classification 
system can be refined as additional data are collected, 
with attention focusing on any dissenting AS cases and 
perceived misunderstanding within the consultation. 
Such inconsistencies will be explored during interviews, 
and discussions will pay attention to differences in patient 
and professional understanding of events.
Audio recordings of observed consultations will be 
listened to in detail by a primary analyst, with a subsample 
of recordings also listened to by a secondary analyst to 
verify the analysis process. Notes from this work will be 
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used as part of feedback discussions between analysts and 
will assist in the development of the preliminary classi-
fication approach. These classifications are expected to 
include the type of consultation (eg, AS monitoring proce-
dures, results given and treatments discussed); when and 
how risk is raised, and by whom, the terminology used to 
convey risk (eg, probabilities, jargon, personal or imper-
sonal and clinical); emotional dimensions of risk; whether 
and how decisions about risk management are made; and 
if decisions are shared with patients.
Stage 2: patient and healthcare professional interview data
Audio recordings of the patient and healthcare profes-
sional interviews will be transcribed by the study team. 
The preliminary classification developed through the 
collection of observation findings will be applied to the 
interview data. Further refinements of the classification 
will lead to the development of a final coding framework, 
agreed on by primary and secondary analysts through 
teamwork meetings, and discussed with wider study 
members through a study team workshop. The coding 
framework, once agreed through consensus, will be used 
to organise interview and observational data according to 
key themes arising in the data.
Thematic analysis will lead to the identification of the 
most frequently occurring themes and their concomitant 
categories to support disclosure of the meanings people 
bring to their health experiences. Thematic significance 
will be determined in line with literature on risk, PCa and 
AS, to focus on the implications of risk and risk consul-
tation.45 46 Triangulation will be conducted by method 
(observation, questionnaire and interview) and by source 
(patient and healthcare professional).47 Verification 
of the subsample of field notes and transcripts by the 
secondary qualitative analyst will add to the veracity of the 
coding framework. Both researchers will use the work-
shop with the wider study team to discuss: the frequency 
and meaning of key themes, corroboration between inter-
view and observational data, differences and similarities 
between patient and healthcare professional data, and 
the completeness of the interpretations made.
EthIcs And dIssEMInAtIon
Ethical approval for the study has been granted by 
Macquarie University Human Research Ethics Committee 
, approval number 5201600638. Data collection and anal-
ysis will be conducted in accordance with National Health 
and Medical Research Council ethical guidelines and 
those of the supporting human ethics research committee. 
All participants will give full, non-coercive consent and 
may withdraw from participation at any time. Procedures 
will be implemented to minimise the potential for harm 
or distress caused to patients, including ethics training 
for interviewers to manage any issues of concern (eg, 
stopping the interview if a participant becomes upset) 
and contact details to be supplied to patients for patient 
support groups. Participant privacy and confidentiality 
will be respected by removing all identifying information 
from data, assigning pseudonyms to participant data and 
storing all study data safely and securely on password-pro-
tected computers or in locked cabinets at the university. 
Physical copies of transcription data will be stored sepa-
rately to patient identifiers. All data will be destroyed after 
7 years in accordance with ethical principles.
Study outputs will take several forms. First, a research 
report will be developed based on the study findings, 
including patients’ needs regarding risk communica-
tion in PCa, support and information for AS. The report 
will make recommendations to healthcare professionals 
regarding optimal strategies for communicating about 
risk, in line with patient need and expectation. Second, 
an executive summary for wide-ranging dissemination 
through public and patient representative groups and 
through healthcare professional groups will be developed 
and distributed on request. Third, peer-reviewed papers 
will be produced for academic journals. Journals will be 
chosen strategically to maximise international appeal and 
extensive interest in study findings. In particular, publi-
cations will be targeted at those healthcare professionals 
working in PCa. Finally, presentations and workshops will 
be prepared for international conferences and to appeal 
to those working within the field who wish to develop 
methodological expertise in mixed-methods applications 
in PCa.
significance and impact of the study
This study acts as proof of concept study, testing out this 
qualitative, multimethod approach in the PCa context in 
Australia for the first time. In examining consultations 
and the experiences of patients who are considering, or 
undergoing an AS protocol, this study will ensure notions 
of risk, and the prioritisation of risk management is effec-
tive and well managed. The study will elucidate patients’ 
and healthcare professionals’ views of, and management 
strategies for, risk communication and risk assessment, 
as well as providing rich details regarding how reduction 
or containment of risk is managed effectively, different 
approaches taken and changes to people’s views through 
the course of initial and subsequent risk assessment for 
PCa. As such, these findings will be essential for PCa risk 
communication development, helping not only to iden-
tify patients’ changing needs for information, support and 
consultation but to know how clinical teams can better 
align service provision to patient need. Finally, these find-
ings will underpin the development of future research in 
the field that focuses on an intervention-based approach 
to underpin risk assessment procedure for multisite, 
large-scale roll-out.
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